{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:01:15Z","timestamp":1792065675788,"version":"4.4.0"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0170874","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T14:38:27Z","timestamp":1485355107000},"page":"e0170874","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease"],"prefix":"10.1371","volume":"12","author":[{"given":"Yun Jung","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Moon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Chul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Lee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ae Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hyun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wookyung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungsik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1271-8012","authenticated-orcid":true,"given":"Ji Yong","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","article-title":"Diabetic nephropathy: diagnosis, prevention, and treatment","volume":"28","author":"JL Gross","year":"2005","journal-title":"Diabetes Care"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'","volume":"84","author":"KM Andrassy","year":"2013","journal-title":"Kidney Int"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"G Mancia","year":"2013","journal-title":"J Hypertens"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"PA James","year":"2014","journal-title":"JAMA"},{"issue":"20","key":"ref5","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"EJ Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"15","key":"ref6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"G Maschio","year":"1996","journal-title":"N Engl J Med"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"EJ Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"BM Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"9069","key":"ref9","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"9176","key":"ref10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"P Ruggenenti","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-127-5-199709010-00001","article-title":"Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group","volume":"127","author":"I Giatras","year":"1997","journal-title":"Ann Intern Med"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-141-2-200407200-00007","article-title":"The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency","volume":"141","author":"CY Hsu","year":"2004","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"ref13","first-page":"S1","article-title":"US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"67","author":"R Saran","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.krcp.2012.01.005","article-title":"Brief Report: Renal replacement therapy in Korea, 2010","volume":"31","author":"DC Jin","year":"2012","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/kisup.2015.3","article-title":"Dialysis registries in the world: Korean Dialysis Registry","volume":"5","author":"DC Jin","year":"2015","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2840-1-2","article-title":"Losartan and diabetic nephropathy: commentaries on the RENAAL study","volume":"1","author":"EZ Fisman","year":"2002","journal-title":"Cardiovasc Diabetol"},{"issue":"9502","key":"ref17","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"JP Casas","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/qjmed\/hcn142","article-title":"Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET\u2014a call for more circumspection","volume":"102","author":"MA Onuigbo","year":"2009","journal-title":"Qjm"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5527\/wjn.v4.i1.118","article-title":"Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy","volume":"4","author":"H Suzuki","year":"2015","journal-title":"World J Nephrol"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1161\/hy1101.099502","article-title":"Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy","volume":"38","author":"P Svensson","year":"2001","journal-title":"Hypertension"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0195-668X(02)00797-2","article-title":"Outcome beyond blood pressure control?","volume":"24","author":"JA Staessen","year":"2003","journal-title":"Eur Heart J"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2215\/CJN.02231205","article-title":"Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade","volume":"1","author":"KA Griffin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"ref23","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"M Rahman","year":"2005","journal-title":"Arch Intern Med"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.ki.5000159","article-title":"ACE-inhibitor use and the long-term risk of renal failure in diabetes","volume":"69","author":"S Suissa","year":"2006","journal-title":"Kidney Int"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"FF Hou","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"FF Hou","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"AS Levey","year":"2003","journal-title":"Ann Intern Med"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2753.2009.01361.x","article-title":"Evaluating health management programmes over time: application of propensity score-based weighting to longitudinal data","volume":"16","author":"A Linden","year":"2010","journal-title":"J Eval Clin Pract"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"JM Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"12","key":"ref31","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/sim.1144","article-title":"Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures","volume":"21","author":"MA Hernan","year":"2002","journal-title":"Stat Med"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/aje\/155.11.1045","article-title":"Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study","volume":"155","author":"NR Cook","year":"2002","journal-title":"Am J Epidemiol"},{"issue":"7160","key":"ref33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"9638","key":"ref34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"JF Mann","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"AK Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11255-007-9299-2","article-title":"Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients","volume":"40","author":"MA Onuigbo","year":"2008","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/08860220701742161","article-title":"Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors","volume":"30","author":"MA Onuigbo","year":"2008","journal-title":"Ren Fail"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","article-title":"Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia","volume":"174","author":"TW Hsu","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","article-title":"Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988\u20131994)","volume":"162","author":"BC Astor","year":"2002","journal-title":"Arch Intern Med"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00041552-200205000-00011","article-title":"Epidemiology of anemia associated with chronic renal insufficiency","volume":"11","author":"CY Hsu","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"c133","DOI":"10.1159\/000312876","article-title":"Prevalence of anemia and its impact on mortality and hospitalization rate in predialysis patients","volume":"115","author":"N Voormolen","year":"2010","journal-title":"Nephron Clin Pract"},{"issue":"17","key":"ref42","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"J Coresh","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semnephrol.2009.06.006","article-title":"Interaction of aging and chronic kidney disease","volume":"29","author":"S Prakash","year":"2009","journal-title":"Semin Nephrol"},{"issue":"3\u20134","key":"ref44","first-page":"787","article-title":"Acute renal failure in the elderly: particular characteristics","volume":"38","author":"CG Musso","year":"2006","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"731","DOI":"10.7326\/0003-4819-150-10-200905190-00014","article-title":"Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?","volume":"150","author":"PA Sarafidis","year":"2009","journal-title":"Ann Intern Med"},{"issue":"282","key":"ref46","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/qjmed\/77.1.997","article-title":"Angiotensin-converting enzyme inhibition and renovascular disease","volume":"77","author":"AE Raine","year":"1990","journal-title":"Q J Med"},{"issue":"6","key":"ref47","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease","volume":"18","author":"DM Kent","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archinte.165.8.947","article-title":"The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension","volume":"165","author":"J Lea","year":"2005","journal-title":"Arch Intern Med"},{"issue":"9","key":"ref49","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.2215\/CJN.08061109","article-title":"Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort","volume":"5","author":"Y Obi","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy","volume":"12","author":"P Ruggenenti","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"ref51","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"LC van Vark","year":"2012","journal-title":"Eur Heart J"},{"issue":"5","key":"ref52","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"J Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"9215","key":"ref53","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"B Pitt","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials","volume":"91","author":"S Bangalore","year":"2016","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"ref55","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker","volume":"1","author":"A Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"ref56","first-page":"Cd007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"D Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"23","key":"ref57","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"HH Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"23","key":"ref58","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"HH Parving","year":"2008","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0170874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T15:56:08Z","timestamp":1658505368000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0170874"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Shimosawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,25]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0170874","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,25]]}}}